You are less likely to need an LMN when: GLP-1 is prescribed for type 2 Diabetes The medication is filled through a standard pharmacy The charge clearly appears as a prescription drug An LMN is more commonly required when semaglutide is prescribed for conditions that plan administrators may classify as dual-purpose
Other important side effects that may affect wellbeing include: Gallbladder problems (pain in the right upper abdomen, fever, jaundice) Dehydration leading to acute kidney injury, especially if vomiting or diarrhoea is severe Worsening of diabetic retinopathy in some patients, particularly with semaglutide Allergic reactions (rash, swelling, breathing difficulties) Patients should report suspected side effects to their healthcare provider and can also report them through the MHRA Yellow Card scheme
P =.002)
On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery
The Food and Drug Administration requires drug companies to run studies investigating whether GLP-1s increase the risk of cardiovascular problems a mandate for all diabetes drugs
In: Office of disease prevention and health promotion USDoHaHS, ed